E Jonasch

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology
    Wassim Kassouf
    Division of Urology, McGill University Health Center, Montreal, Quebec, Canada
    J Urol 178:1896-900. 2007
  2. ncbi Patterns of intervention for renal lesions in von Hippel-Lindau disease
    Surena F Matin
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    BJU Int 102:940-5. 2008
  3. ncbi Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma
    Amado J Zurita
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, TX 77030 4009, USA
    Cancer 115:2346-54. 2009
  4. ncbi Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease
    E Jonasch
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Ann Oncol 22:2661-6. 2011
  5. ncbi Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
    Eric Jonasch
    Department of Genitourinary Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 113:72-7. 2008
  6. ncbi Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings
    E Jonasch
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, Texas 77030, USA
    Br J Cancer 98:1336-41. 2008
  7. ncbi Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma
    Eric Jonasch
    Department ofGenitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 27:4076-81. 2009
  8. ncbi Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis
    Eric Jonasch
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:57-65. 2010
  9. ncbi Presurgical therapy in metastatic renal cell carcinoma
    Eric Jonasch
    UT MD Anderson Cancer Center, GU Medical Oncology, Unit 1374, PO Box 301439, Houston, TX 77230 1439, USA
    Expert Rev Anticancer Ther 7:73-8. 2007
  10. ncbi Targeted therapy for locally advanced renal cell carcinoma
    Eric Jonasch
    The University of Texas M D Anderson Cancer Center, GU Medical Oncology Unit 1374, PO Box 301439, Houston, TX 77230 1439, USA
    Target Oncol 5:113-8. 2010

Detail Information

Publications40

  1. ncbi Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology
    Wassim Kassouf
    Division of Urology, McGill University Health Center, Montreal, Quebec, Canada
    J Urol 178:1896-900. 2007
    ..D. Anderson Cancer Center. We compared the outcomes with those in patients with clear cell metastatic renal cell carcinoma...
  2. ncbi Patterns of intervention for renal lesions in von Hippel-Lindau disease
    Surena F Matin
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    BJU Int 102:940-5. 2008
    ..To review the records of patients at our centre with von Hippel-Lindau (VHL) disease, to determine the incidence of renal cell carcinoma (RCC) and patterns of intervention using minimally invasive therapies...
  3. ncbi Circulating biomarkers for vascular endothelial growth factor inhibitors in renal cell carcinoma
    Amado J Zurita
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, TX 77030 4009, USA
    Cancer 115:2346-54. 2009
    ..Further preclinical and translational validation studies are still needed to determine their practical utility in the clinical setting...
  4. ncbi Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease
    E Jonasch
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, 77030, USA
    Ann Oncol 22:2661-6. 2011
    ..Von Hippel-Lindau (VHL) disease induces vascular neoplasms in multiple organs. We evaluated the safety and efficacy of sunitinib in VHL patients and examined the expression of candidate receptors in archived tissue...
  5. ncbi Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
    Eric Jonasch
    Department of Genitourinary Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 113:72-7. 2008
    ..The purpose of the current study was to evaluate the activity and safety of TLF in patients with refractory metastatic renal cell carcinoma (RCC)...
  6. ncbi Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings
    E Jonasch
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1374, Houston, Texas 77030, USA
    Br J Cancer 98:1336-41. 2008
    ..Treatment with vitespen did not result in a discernable benefit in the majority of patients with metastatic RCC treated in this study. Use in combination with immunoregulatory agents may enhance the efficacy of vitespen...
  7. ncbi Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma
    Eric Jonasch
    Department ofGenitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, PO Box 301439, Houston, TX 77230 1439, USA
    J Clin Oncol 27:4076-81. 2009
    ....
  8. ncbi Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis
    Eric Jonasch
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer 116:57-65. 2010
    ..The objective of this study was to independently evaluate the objective response rate of sorafenib and sorafenib plus low-dose interferon-alfa 2b (IFN) as frontline therapy in patients with metastatic renal cell carcinoma (mRCC)...
  9. ncbi Presurgical therapy in metastatic renal cell carcinoma
    Eric Jonasch
    UT MD Anderson Cancer Center, GU Medical Oncology, Unit 1374, PO Box 301439, Houston, TX 77230 1439, USA
    Expert Rev Anticancer Ther 7:73-8. 2007
    ....
  10. ncbi Targeted therapy for locally advanced renal cell carcinoma
    Eric Jonasch
    The University of Texas M D Anderson Cancer Center, GU Medical Oncology Unit 1374, PO Box 301439, Houston, TX 77230 1439, USA
    Target Oncol 5:113-8. 2010
    ..Future trials using agents with optimized cytoreductive capabilities in conjunction with therapies capable of preventing metastatic dissemination may improve the outcomes of patients with locally advanced renal cell carcinoma...
  11. ncbi Adjuvant and neoadjuvant therapy in renal cell carcinoma
    Eric Jonasch
    UT M D Anderson Cancer Center, Genitourinary Medical Oncology, Houston, TX 77030, USA
    Cancer J 14:315-9. 2008
    ..Additional questions arise about timing or therapy in the high risk setting. If an effective treatment exists, should it be given before or after nephrectomy? Potential strategies to answer these questions are outlined in the manuscript...
  12. ncbi Long-term management of patients with metastatic renal cell carcinoma on targeted agents
    Eric Jonasch
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, 77230 1439, USA
    Expert Rev Anticancer Ther 10:1883-9. 2010
    ..As treatment efficacy improves, the optimal integration of systemic therapy, surgery and toxicity management will become a critical aspect of our care for patients with metastatic renal cell carcinoma...
  13. ncbi Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine and bevacizumab at a tertiary cancer centre
    Eric Jonasch
    Genitourinary Medical Oncology Clinical Pharmacy Services, Division of Pharmacy, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    BJU Int 107:741-7. 2011
    ..To investigate the effect of combining gemcitabine plus capecitabine (GX) with bevacizumab (A) in patients with metastatic RCC previously treated with cytokines and targeted agents...
  14. ncbi Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma
    Vitaly Margulis
    Department of Urology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 180:94-8. 2008
    ....
  15. ncbi Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy
    S L Richey
    Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, TX, USA
    Ann Oncol 22:1048-53. 2011
    ..Historically, median overall survival (OS) of patients treated with interferon alpha (IFN-α) without CN was 7.8 months. Median OS in patients treated with targeted therapy (TT) without CN is unknown...
  16. ncbi Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma
    D Tsavachidou-Fenner
    Department of Systems Biology, University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Ann Oncol 21:1599-606. 2010
    ..Metastatic renal cell carcinoma (mRCC) patients treated with anti-vascular endothelial growth factor (VEGF) therapies demonstrate promising outcomes but not all patients benefit. Factors that predict response remain to be elucidated...
  17. ncbi A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma
    A J Zurita
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 23:46-52. 2012
    ..We aimed to link the CAF profile to PFS and select candidate predictive and prognostic markers for further study...
  18. ncbi Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-alpha: association of pretreatment serum levels with survival
    A J Montero
    Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Ann Oncol 20:1682-7. 2009
    ..To correlate serum cytokine and angiogenic factor (CAF) levels with overall survival (OS) in metastatic renal cell carcinoma (mRCC) treated with interferon-alpha (IFN-alpha)...
  19. ncbi Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes
    Alan Rodney
    Department of Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:2143-7. 2006
    ..CONCLUSIONS: The combination of capecitabine and gemcitabine for the salvage treatment of patients with AIPCa was associated with significant toxicities and was ineffective for induction of disease regression...
  20. ncbi Papillary renal cell carcinoma: radiologic-pathologic correlation and spectrum of disease
    Raghunandan Vikram
    Department of Diagnostic Radiology, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Radiographics 29:741-54; discussion 755-7. 2009
    ..A mass that enhances to a lesser degree is likely to be a non-clear cell RCC. It is common for metastatic lesions from pRCC to show enhancement characteristics similar to those of the primary tumor and be hypovascular...
  21. ncbi Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib
    Zita Dubauskas
    Department of Genitourinary Medical Oncology, The University of Texas Health Science Center, Houston, TX 77030, USA
    Clin Genitourin Cancer 7:20-3. 2009
    ..Cutaneous squamous cell carcinoma (SCC) and inflammation of actinic keratosis (AK) were reported in 2 patients treated with sorafenib (Lacouture et al), but the scope of this observation has not been evaluated...
  22. ncbi Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors
    Camilo Jimenez
    Department of Endocrine Neoplasia and Hormonal Disorders, Unit 435, The University of Texas M D Anderson Cancer, Center, Houston, Texas 77030, USA
    J Clin Endocrinol Metab 94:386-91. 2009
    ..von Hippel-Lindau disease is characterized by highly vascularized tumors of multiple organs...
  23. ncbi Randomized trial of adjuvant thalidomide versus observation in patients with completely resected high-risk renal cell carcinoma
    Vitaly Margulis
    Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Urology 73:337-41. 2009
    ..To evaluate the effect of adjuvant thalidomide on recurrence-free survival (RFS) after nephrectomy for high-risk metastatic renal cell carcinoma (RCC)...
  24. ncbi Current status of debulking nephrectomy in the era of tyrosine kinase inhibitors
    Vitaly Margulis
    Department of Urology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Oncol Rep 10:253-8. 2008
    ..Until then, debulking surgery, which provides a survival benefit for select patients with mRCC, should continue to be used in patients before or after targeted systemic therapy...
  25. ncbi Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes
    Kamran Ahrar
    The Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, 77030 4009, USA
    J Vasc Interv Radiol 16:679-88. 2005
    ..To report the safety, technical success, and effectiveness of percutaneous radiofrequency (RF) ablation for renal tumors...
  26. ncbi Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma
    Nizar Tannir
    Department of Genitourinary Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77230, USA
    Cancer 107:497-505. 2006
    ....
  27. ncbi Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carci
    Nizar M Tannir
    Department of Genitourinary Medical Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 107:2254-61. 2006
    ..In a randomized Phase II trial, the authors tested the hypothesis that twice-daily low-dose IFN is more effective than daily intermediate-dose IFN in patients with metastatic renal cell cancer (MRCC)...
  28. ncbi Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
    Naoto T Ueno
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 448, Houston, TX 77030, USA
    Blood 102:3829-36. 2003
    ..It induces rapid complete donor chimerism without the need for donor lymphocyte infusion. Tumor regression associated with GVHD is consistent with graft-versus-tumor effect...
  29. ncbi A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents
    Nizar M Tannir
    Genitourinary Medical Oncology Department, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 180:867-72; discussion 872. 2008
    ..We assessed the clinical activity and safety of gemcitabine plus capecitabine in patients with metastatic renal cell cancer previously treated with immunotherapy...
  30. ncbi Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment
    E Jason Abel
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 184:1877-81. 2010
    ..We assessed the accuracy of percutaneous primary tumor biopsy for metastatic renal cell carcinoma by comparing biopsy findings to final nephrectomy pathology in patients undergoing cytoreductive nephrectomy...
  31. ncbi Cytoreductive nephrectomy in the elderly patient: the M. D. Anderson Cancer Center experience
    A Karim Kader
    Department of Urology, University of Texas, M D Anderson Cancer Center, Houston, Texas, USA
    J Urol 177:855-60; discussion 860-1. 2007
    ..The benefit in the elderly population (75 years or older) is unclear. We reviewed our experience to help determine if it is of benefit in this patient population...
  32. ncbi Radio frequency ablation of renal tumors in patients with metastatic renal cell carcinoma
    Jose A Karam
    Department of Urology, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    J Urol 184:1882-7. 2010
    ....
  33. ncbi A novel von Hippel-Lindau point mutation presents as apparently sporadic pheochromocytoma
    Thereasa A Rich
    Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4009, USA
    Cancer Invest 26:642-6. 2008
    ..The nearly asymptomatic patient's father also carries the same mutation. Similar to other mutations localized in the same codon, the Gly104Val VHL mutation seems to have an attenuated disease phenotype...
  34. ncbi Port-site metastasis: the influence of biology
    Ralph A Highshaw
    Department of Urology, University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Eur Urol 47:357-60. 2005
    ..This unusual case highlights the important role that tumor and host biologic mechanisms play in the development of port-site metastasis...
  35. ncbi Cytoplasmic sequestration of p27 via AKT phosphorylation in renal cell carcinoma
    Jinhee Kim
    Department of Carcinogenesis, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Clin Cancer Res 15:81-90. 2009
    ..p27 localization and expression has prognostic and predictive value in cancer. Little is known regarding expression patterns of p27 in renal cell carcinoma (RCC) or how p27 participates in disease progression or response to therapy...
  36. ncbi Adjuvant and neoadjuvant therapy in renal cell carcinoma
    Michel Choueiri
    University of California, San Diego, La Jolla, CA 92093, USA
    Curr Clin Pharmacol 6:144-50. 2011
    ..There is optimism that locally advanced RCC might benefit from adjuvant or neoadjuvant treatment with these therapies. Ongoing clinical trials are addressing the role of targeted agents in this disease state...
  37. ncbi Inhibition of Mxi1 suppresses HIF-2alpha-dependent renal cancer tumorigenesis
    Chun Chui Tsao
    Department of Genitourinary Medical Oncology, MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer Biol Ther 7:1619-27. 2008
    ..Compared to Mxi1-proficient tumors, Mxi1-deficient tumors display reduced cellular proliferation. These results establish Mxi1 as an important downstream target of HIF that contributes to pVHL-deficient renal cancer tumorigenesis...
  38. ncbi Cytoreductive nephrectomy for T4NxM1 renal cell carcinoma: the M.D. Anderson Cancer Center experience
    Wassim Kassouf
    Department of Urology, McGill University Health Center, Montreal, Quebec, Canada
    Urology 69:835-8. 2007
    ..We reviewed our experience with cytoreductive nephrectomy in patients with contiguous organ involvement (Stage T4NxM1) to evaluate the outcome and morbidity...
  39. ncbi Kidney cancer. Clinical practice guidelines in oncology
    Robert J Motzer
    J Natl Compr Canc Netw 4:1072-81. 2006
  40. ncbi Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute
    Kenneth A Katz
    Department of Dermatology, University of Pennsylvania, Philadelphia, PA 19104, USA
    Melanoma Res 15:77-82. 2005
    ..The demographic and survival characteristics of this MUP cohort mirrored those found in previous studies. More studies of MUP patients, as well as a standardized definition of MUP, may shed light on the pathogenesis and prognosis of MUP...